From a technical perspective, Sensus Healtheare, Inc. (SRTS) is looking like an interesting pick, as it just reached a key level of support. SRTS recently overtook the 20-day moving average, and this suggests a short-term bullish trend. The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short- term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal sig ...

Financial Performance - Revenues for the three months ended June 30, 2024, were $9.2 million, an increase of 104.4% compared to $4.5 million for the same period in 2023[79] - Gross profit for the three months ended June 30, 2024, was $5.4 million, representing a 107.7% increase from $2.6 million in the same period in 2023[81] - Net income for the three months ended June 30, 2024, was $1.6 million, compared to a net loss of $0.4 million for the same period in 2023[78] - Revenues for the six months ended June 30, 2024, were $20.0 million, an increase of 151.9% compared to $8.0 million for the same period in 2023[83] - Gross profit for the six months ended June 30, 2024, was $12.1 million, an increase of 188.1% from $4.2 million in the same period in 2023[84] Cash Flow and Receivables - Cash and cash equivalents decreased by $4.1 million from December 31, 2023, to June 30, 2024[89] - Accounts receivable increased by $7.7 million from December 31, 2023, primarily due to increased sales and extended payment terms[89] Expenses - Selling and marketing expenses decreased by 37.5% to $1.0 million for the three months ended June 30, 2024, compared to $1.6 million for the same period in 2023[82] - Research and development expenses increased by 12.5% to $0.9 million for the three months ended June 30, 2024, due to a project for a drug delivery system[83] Economic Factors - The company continues to monitor inflationary pressures and is taking actions to minimize its effects on product costs and sales[94]

Core Viewpoint - Sensus Healthcare, Inc. (SRTS) shows potential for significant upside, with a mean price target of $10 indicating a 64.7% increase from the current price of $6.07 [1] Price Target Analysis - The mean estimate consists of three short-term price targets with a standard deviation of $0, indicating strong agreement among analysts [2] - The lowest estimate of $10 suggests a 64.7% increase from the current price, while the most optimistic analyst also expects the stock to reach $10 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [5][6] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding SRTS's ability to report better earnings than previously predicted supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has a strong correlation with near-term stock price movements [9] - Over the last 30 days, two earnings estimates for SRTS have increased, leading to a 20% rise in the Zacks Consensus Estimate [10] Zacks Rank and Investment Potential - SRTS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - While the consensus price target may not be a reliable indicator of potential gains, the implied direction of price movement appears to be a good guide [11]

Financial Data and Key Metrics Changes - Revenues for Q2 2024 more than doubled to $9.2 million, up 104% from $4.5 million in Q2 2023, driven by a higher number of SRT systems sold [9][12] - Net income for Q2 2024 was $1.6 million or $0.10 per diluted share, compared to a net loss of $0.4 million or $0.02 per share in Q2 2023 [11] - Adjusted EBITDA for Q2 2024 was $2.1 million compared to negative $1 million in Q2 2023 [11] Business Line Data and Key Metrics Changes - The company shipped 23 systems during Q2 2024, compared to 13 systems in the same quarter last year [4][9] - The Fair Deal Agreement program has 15 signed contracts, with expectations to reach up to 50 by year-end [5][17] Market Data and Key Metrics Changes - The company has expanded its international sales, with the first-ever image-guided SRT-100 Vision system sold in Asia [8] - The largest market outside the U.S. remains China, where two additional SRT-100 systems were shipped [8] Company Strategy and Development Direction - The company is focusing on a recurring revenue model through the Fair Deal Agreement, which allows customers to allocate capital to other areas of their business [5][17] - The company aims to open two to three new international territories per year, having successfully opened sales to Ireland, Guatemala, and Turkey [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential of SRT treatments for non-melanoma skin cancer and keloids, citing a 27% annual growth rate in Medicare claims for SRT [18] - The company anticipates significant recurring revenues beginning in 2025, with a strong volume projected for the second half of that year [5][18] Other Important Information - Cash and cash equivalents were $19 million as of June 30, 2024, down from $23.1 million at the end of 2023 [14][15] - The company is focused on maintaining a strong balance sheet to capitalize on growth opportunities [15] Q&A Session Summary Question: Can you provide details on the Fair Deal Agreement placements? - Management confirmed that all placements will be installed this year, primarily in Q4, allowing for revenue generation starting in early 2025 [20] Question: What is the total number of agreements signed to date? - Management confirmed that there are currently 15 agreements signed since the introduction of the program in March [22] Question: Are you supply constrained this year due to orders? - Management indicated that they have sufficient supply to meet customer needs and have placed orders for additional units [23] Question: How should we model the Fair Deal Agreements going into next year? - Management suggested that the Fair Deal Agreement provides reasonable terms for customers, making it easier for them to implement [24] Question: Can you provide a breakdown of domestic and international sales? - Management confirmed that out of 23 total sales, 20 were domestic and 3 were international [38]

Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 233.33%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.14, delivering a surprise of 450%. Over the last four quarters, the compa ...

The stock market bounced back on Tuesday following Monday's market-wide selloff. Stocks were due for a pullback following the huge first-half rally, and the recent wave of selling has helped cool off the market. Despite the possibility of more near-term selling and volatility, the last several years highlight why investors must attempt to stay exposed to the stock market at all times. Investors who want to buy stocks in August and the rest of the summer might consider searching for stocks gaining more atten ...

The most recent trading session ended with Sensus Healthcare, Inc. (SRTS) standing at $6.25, reflecting a -1.88% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 1.37%. Meanwhile, the Dow experienced a drop of 1.21%, and the technology-dominated Nasdaq saw a decrease of 2.3%. Coming into today, shares of the company had gained 25.64% in the past month. In that same time, the Medical sector gained 0.74%, while the S&P 500 gained 1.11%. The upcoming ...

BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and nononcological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Parti ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate re ...

Sensus Healthcare, Inc. (SRTS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. Thes ...